Wet Age-Related Macular Degeneration (AMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 The most common cause of visual impairment among elderly patients in developed countries is wet age-related macular degeneration (ARMD), which is characterized by the growth of choroidal neovascularization (CNV) driven by vascular endothelial growth factor (VEGF). CNV can result in bleeding under the retina, detachment or atrophy of the retinal pigment epithelium (RPE), or fluid accumulation under the retina or RPE, leading to vision loss. Wet ARMD differs from dry ARMD by the presence of CNV, where new blood vessels from the choroid invade Bruch's membrane and proliferate either between the membrane and RPE or in the subretinal space. The multifactorial nature of wet ARMD includes numerous risk factors such as older age, elevated total serum cholesterol, micronutrient deficiency, smoking, family history, hypertension, cardiovascular disease, and visible light exposure. Genetic predisposition to ARMD is also apparent, with at least 34 genetic loci and 52 gene variants associated with the disease. Without treatment, most patients with wet ARMD will suffer irreversible vision loss.

·       Approximately 10% of patients with ARMD develop neovascular disease. In the absence of anti-VEGF therapy, between 79% to 90% of those eyes will eventually become legally blind due to complications from neovascularization.

 

Thelansis’s “Wet Age-Related Macular Degeneration (AMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wet Age-Related Macular Degeneration (AMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Wet Age-Related Macular Degeneration (AMD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Wet Age-Related Macular Degeneration (AMD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Wet Age-Related Macular Degeneration (AMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Wet Age-Related Macular Degeneration (AMD), Wet Age-Related Macular Degeneration (AMD) market outlook, Wet Age-Related Macular Degeneration (AMD) competitive landscape, Wet Age-Related Macular Degeneration (AMD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)